Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ciforadenant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ciforadenant overview
Ciforadenant is under development for the treatment of solid tumors such as non-small cell lung cancer, malignant melanoma, renal cell carcinoma, triple negative breast cancer, and metastatic castration-resistant prostate cancer, head and neck cancer, colorectal cancer with microsatellite instability (MSI),n oropharyngeal cancers associated with HPV infection, bladder cancer,cervical cancer, uterine cancer, sarcoma, relapsed or refractory multiple myeloma, endometrial cancer (as a second and third line therapy) and metastatic renal cell carcinoma. It is administered through oral route in the form of capsule. The drug candidate is a small molecule which acts by targeting A2A receptor. It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. It is a backup drug of BIIB014 (vipadenant).
See Also:
Corvus Pharmaceuticals overview
Corvus Pharmaceuticals (Corvus Pharma) is a clinical-stage biopharmaceutical company. It operates in the development and commercialization of immuno-oncology therapies that are used for treating cancer. It offers pipeline products such as CPI-818, A2A inhibitor, ciforadenant (CPI-444), mupadolimab (CPI-006) and others. Corvus Pharma’s product CPI-444 is an oral small molecule antagonist that blocks the A2A receptor. The company also develops a product candidate an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline also includes adenosine A2B receptor antagonists ITK inhibitors and myeloid cell suppression. The company operates in the US and the Cayman Islands. Corvus Pharma is headquartered in Burlingame, California, US.
For a complete picture of Ciforadenant’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
